263 related articles for article (PubMed ID: 27404565)
1. Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position.
Tolan D; Gandin V; Morrison L; El-Nahas A; Marzano C; Montagner D; Erxleben A
Sci Rep; 2016 Jul; 6():29367. PubMed ID: 27404565
[TBL] [Abstract][Full Text] [Related]
2. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
3. Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cells.
Almotairy ARZ; Montagner D; Morrison L; Devereux M; Howe O; Erxleben A
J Inorg Biochem; 2020 Sep; 210():111125. PubMed ID: 32521289
[TBL] [Abstract][Full Text] [Related]
4. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.
Ravera M; Gabano E; Zanellato I; Bonarrigo I; Alessio M; Arnesano F; Galliani A; Natile G; Osella D
J Inorg Biochem; 2015 Sep; 150():1-8. PubMed ID: 26042542
[TBL] [Abstract][Full Text] [Related]
5. Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.
Cetraz M; Sen V; Schoch S; Streule K; Golubev V; Hartwig A; Köberle B
Arch Toxicol; 2017 Feb; 91(2):785-797. PubMed ID: 27307157
[TBL] [Abstract][Full Text] [Related]
6. Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects.
Tabrizi L; Thompson K; Mnich K; Chintha C; Gorman AM; Morrison L; Luessing J; Lowndes NF; Dockery P; Samali A; Erxleben A
Mol Pharm; 2020 Aug; 17(8):3009-3023. PubMed ID: 32628022
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations.
Song Y; Suntharalingam K; Yeung JS; Royzen M; Lippard SJ
Bioconjug Chem; 2013 Oct; 24(10):1733-40. PubMed ID: 23957697
[TBL] [Abstract][Full Text] [Related]
8. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
9. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
[TBL] [Abstract][Full Text] [Related]
10. Effective platinum(IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria.
Chen H; Chen F; Hu W; Gou S
J Inorg Biochem; 2018 Mar; 180():119-128. PubMed ID: 29253663
[TBL] [Abstract][Full Text] [Related]
11. Stability, Reduction, and Cytotoxicity of Platinum(IV) Anticancer Prodrugs Bearing Carbamate Axial Ligands: Comparison with Their Carboxylate Analogues.
Chen S; Yao H; Zhou Q; Tse MK; Gunawan YF; Zhu G
Inorg Chem; 2020 Aug; 59(16):11676-11687. PubMed ID: 32799457
[TBL] [Abstract][Full Text] [Related]
12. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
[TBL] [Abstract][Full Text] [Related]
13. Improving of Anticancer Activity and Solubility of Cisplatin by Methylglycine and Methyl Amine Ligands Against Human Breast Adenocarcinoma Cell Line.
Shams Abyaneh FS; Eslami Moghadam M; Divsalar A; Ajloo D; Hosaini Sadr M
Appl Biochem Biotechnol; 2018 Oct; 186(2):271-291. PubMed ID: 29516403
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates.
Novohradsky V; Zanellato I; Marzano C; Pracharova J; Kasparkova J; Gibson D; Gandin V; Osella D; Brabec V
Sci Rep; 2017 Jun; 7(1):3751. PubMed ID: 28623355
[TBL] [Abstract][Full Text] [Related]
15. Dual-acting antitumor Pt(iv) prodrugs of kiteplatin with dichloroacetate axial ligands.
Savino S; Gandin V; Hoeschele JD; Marzano C; Natile G; Margiotta N
Dalton Trans; 2018 May; 47(21):7144-7158. PubMed ID: 29766157
[TBL] [Abstract][Full Text] [Related]
16. Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be?
Zanellato I; Bonarrigo I; Colangelo D; Gabano E; Ravera M; Alessio M; Osella D
J Inorg Biochem; 2014 Nov; 140():219-27. PubMed ID: 25171667
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity and cellular response mechanisms of water-soluble platinum(II) complexes of lidocaine and phenylcyanamide derivatives.
Tabrizi L; Chiniforoshan H
Biometals; 2017 Feb; 30(1):59-70. PubMed ID: 27995355
[TBL] [Abstract][Full Text] [Related]
18. The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions.
Gabano E; Ravera M; Trivero F; Tinello S; Gallina A; Zanellato I; Gariboldi MB; Monti E; Osella D
Dalton Trans; 2018 Jun; 47(25):8268-8282. PubMed ID: 29892758
[TBL] [Abstract][Full Text] [Related]
19. Platinum(II) carboxylato complexes containing 7-azaindoles as N-donor carrier ligands showed cytotoxicity against cancer cell lines.
Štarha P; Trávníček Z; Pazderová L; Dvořák Z
J Inorg Biochem; 2016 Sep; 162():109-116. PubMed ID: 27350081
[TBL] [Abstract][Full Text] [Related]
20. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
Jin S; Guo Y; Song D; Zhu Z; Zhang Z; Sun Y; Yang T; Guo Z; Wang X
Inorg Chem; 2019 May; 58(9):6507-6516. PubMed ID: 31013065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
